## AMENDMENTS TO THE SPECIFICATION

On page 24, after the first paragraph, please amend Table 1 as follows:

TABLE 1

Example Number	R <sub>6</sub>	*NMR	**Mass Spec	Name
1	H H CF3	<sup>1</sup> H NMR in DMSO-d <sub>6</sub> : δ 11.35(d, 1H); 8.08(d, 2H); 7.92(d, 2H); 5.799(s, 2H); 3.29(brs, 4H), 1.17(m, 2H); 0.26(m, 1H) 0.078(s, 1H)	375 (M-H)-	4-Trifluoromethyl-N- (3,3a,4,4a,5,5a,6 6a,- octahydro-1,3-dioxo- 4,6- ethenocycloprop[f]isoi ndol-2(1H)-yl)- benzamide

Example Number	$ m R_6$	*NMR	**Mass Spec	Name
2	H H H H H H H H H H H H H H H H H H H	<sup>1</sup> H NMR in DMSO-d <sub>6</sub> : δ 11.41(brs); 11.15(brs); 8.77(d, of d, 2H); 7.75(d, 2H); 5.77(brs, 2H); 3.27 (brs, 4H), 1.15(brs, 2H); 0.25(m, 1H; 0.03(brs, 1H))	308 (M-H)-	N- (3.3a,4.4a,5.5a,6.6a,- octahydro-1,3-dioxo- 4,6- cthenocycloprop[f]isoi ndol-2(1H)-yl)-4- pyridinecarboxamide
3	H H D O O D D D D D D D D D D D D D D D	***	385 (M-H)-	4-Bromo-N- (3,3a,4,4a,5,5a,6,6a,- octahydro-1,3-dioxo- 4,6- ethenocycloprop[f]isoi ndol-2(1H)-yl)- benzamide

Example Number	$ m R_6$	*NMR	**Mass Spec	Name
4	H H N N N N N N N N N N N N N N N N N N	<sup>1</sup> H NMR in DMSO-d <sub>6</sub> : δ 11.13(brd, 111.13(brd, 11H); 7.99(s, 11H); 7.99(s, 11H); 7.99(s, 11H); 7.92(s, 2H); 5.72(s, 2H), 3.22-3.08(m, 4H); 1.19(brs, 2H; 0.21(m, 1H); 0.17(brs, 1H)	385 (M-H)-	3-Bromo-N- (3,3a,4,4a,5,5a,6,6a,- octahydro-1,3-dioxo- 4,6- ethenocycloprop[f]isoi ndol-2(1H)-yl)- benzamide
5	H N N N N N N N N N N N N N N N N N N N	<sup>1</sup> H NMR in DMSO-d <sub>c</sub> ; δ 11.21(brd, 1H); 1.98(brd, 1H); 7.92(s, 1H); 7.85(d, 1H); 7.71(d, 1H); 7.58(t, 1H); 5.79(brs, 2H); 3.29-3.15(m, 4H); 1.19-1.15(m, 2H); 0.10(brs, 1H)	341 (M-H)-	3-Chloro-N- (3,3a,4,4a,5,5a,6,6a,- octalydro-1,3-dioxo- 4,6- ethenocycloprop[f]isoi ndol-2(1H)-yl)- benzamide

Example Number	$ m R_6$	*NMR	**Mass Spec	Name
6	H H H D O O D D D D D D D D D D D D D D	<sup>1</sup> H NMR in CDCl <sub>3</sub> ; δ 7.74(s, 1H); 7.69(d, 1H); 7.69(d, 1H); 7.63(d, 1H); 7.41-7.31(m, 2H); 5.84(m, 2H); 3.14(s, 2H); 1.19(m, 2H); 3.2H; 0.38-0.20(m, 2H)	385 (M-H-)	2-Bromo-N- (3,3a,4,4a,5,5a,6,6a,- octahydro-1,3-dioxo- 4,6- ethenocycloprop[f]isoi ndol-2(1H)-yl)- benzamide
7	H H CI	<sup>1</sup> H NMR in CDCl <sub>3</sub> : $\delta$ 7,96(s, 1H); 7.83(d, 1H); 7.45(m, 2H); 7.36(m, 1H); 5.86(d, 2H); 3.47(brs, 2H), 3.15(s, 2H); 1.15(brs, 2H); 0.39- 0.20(m, 2H)	341 (M-H)-	2-Chloro-N- (3,3a,4,4a,5,5a,6,6a,- octahydro-1,3-dioxo- 4,6- ethenocycloprop[f]isoi ndol-2(1H)-yl)- benzamide

Example Number	$ m R_6$	*NMR	**Mass Spec	Name
8	T Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	"H NMR in DMSO-d <sub>e</sub> ; δ 11.16(brd, 1H); 10.91(brd, 1H); 7.90(d, 2H); 5.79(s, 2H); 3.28(m, 4H), 1.17(s, 2H); 0.26(m, 1H); 0.07(s, 2H)	341 (M-)H-	4-Chloro-N- (3,3a,4,4a,5,5a,6,6a,- octahydro-1,3-dioxo- 4,6- ethenocycloprop[1]isoi ndol-2(1H)-yl)- benzamide
9	H H H N N N N N N N N N N N N N N N N N	<sup>1</sup> H NMR in DMSO-d <sub>6</sub> : δ 11.33(brd, 1H); 9.04(s, 1H); 8.8(m, 1H); 8.23(d, 1H); 7.56(m, 1H); 5.80(s, 2H), 3.29(m, 2H); 0.27(m, 1H); 0.07(s, 1H)	308 (M-)H-	N- (3,3a,4,4a,5,5a,6,6a,- octahydro-1,3-dioxo- 4,6- ethenocycloprop[f]isoi ndol-2(1H)-yl)-3- pyridinecarboxamide

Example Number	$ m R_6$	*NMR	**Mass Spec	Name
10	H H H H Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	<sup>1</sup> H NMR in DMSO-d <sub>6</sub> : δ 11.11(s, 1H); 8.70(d, 1H); 8.07-8.02(M, 2H); 7.7- 7.66(m, 1H); 3.295(s, 4H), 1.16(m, 2H); 0.27(m, 1H); 0.10(s, 1H)	308 (M-H)-	N- (3,3a,4.4a,5.5a,6,6a,- octahydro-1,3-dioxo- 4,6- eithenocycloprop[f]isoi ndol-2(1H)-yl)-2- pyridinecarboxamide
11	H H N N N N N N N N N N N N N N N N N N	<sup>1</sup> H NMR in DMSO-d <sub>c</sub> ; δ 10.87(brd, 1H); 7.87(d, 2H); 7.05(d, 2H); 5.78(br, 2H); 3.84(s, 3H); 3.30(s, 4H), 1.16(m, 2H); 0.07(brs, 1H)	339 (M+H) <sup>+</sup>	4-Methoxy-N- (3.3a, 4.4a, 5.5a, 6.6a,- octahydro-1, 3-dioxo- 4,6- ethenocyloprop[r]isoi ndol-2(1H)-yl)- benzamide

Example Number	$R_6$	*NMR	**Mass Spec	Name
12	H H H NO2	<sup>1</sup> H NMR in DMSO-d <sub>6</sub> ; δ 11.537- 11.469(brd, 1H); 8.38(d, 2H); 5.80(s, 2H); 3.3(br, 4H); 1.18(s, 2H); 0.27(m, 1H); 0.08(s, 1H)	352 (M-H)-	4-Nitro-N-(3,3a,44a,5,5a,6,6a,-octahydro-1,3-dioxo-4,6-eithenocycloprop[f]isoi ndol-2(HH-yl)-benzamide
13	H H N N N N N N N N N N N N N N N N N N	<sup>1</sup> H NMR in DMSO-d <sub>6</sub> : δ 11.04(br, 1H); 7-96(s, 2H); 7-367(t, 2H); 5-79(s, 2H); 3.258(4H & H <sub>2</sub> O), 1.18(d, 2H); 0.28(m, 1H); 0.09(s, 1H)	327.0 (M+H) <sup>+</sup>	4-Fluoro-N- (3,3a,4,4a,5,5a,6,6a,- octahydro-1,3-dioxo- 4,6- ethenocycloprop[f]isoi ndol-2(1H)-yl)- benzamide

Example Number	$ m R_6$	*NMR	**Mass Spec	Name
14	H H H H H H H H H H H H H H H H H H H	<sup>1</sup> H NMR in DMSO-d <sub>e</sub> : δ 11.176(br, 1H); 7.768- 7.459(m, 4H); 5.797(s, 2H); 3.293(H,O & 4H), 1.174(s, 2H); 0.23(m, 1H); 0.05(s, 1H)	327.0 (M+H) <sup>±</sup>	3-Fluoro-N- (3,3a,4,4a,5,5a,6,6a,- octahydro-1,3-dioxo- 4,6- cthenocycloprop[f]isoi ndol-2(1H)-yl)- benzamide
15	H I I I I I I I I I I I I I I I I I I I	***	388.9 (M-H)-	4-Brome-N- (cotahydro-1,3-dioxo-4,6- ethanoeyelopropf(fliaei ndol-2(HF)-yi) benzamide  4-Brome-N- (3,3a,44a,5,5a,6,6a- octahydro-1,3-dioxo-4,6- ethanocyelopropf(fliaei ndol-2(HF)-yi) benzamide

Example Number	$R_6$	*NMR	**Mass Spec	Name
16	H O O Br	<sup>1</sup> H NMR in DMSO-d <sub>6</sub> : δ 11.14(brd, 1H); 7.85(brd, 2H); 7.76(d, 2H); 6.10(brs, 2H) 3.43(brd, 2H); 1.98-1.54(m, 6H)	387 (M-H)-	4-Bromo-N-(1,3-(2H, 3aH)-dioxo-4,8-ethenocyclohepta[c]py rrolyl)-benzamide
17	N-N <sub>H</sub> Br	"H NMR in DMSO-d <sub>6</sub> : δ 11.16(s, 1H); 7.86(d, 2H); 7.78 (d, 2H); 1.78 (d, 2H); 1.168 (brm, 4H); 1.42 (br, 4H); 5.797(s; 2H); 0.23(H, 0.& 4H), 1.174(s; 2H); 0.23(m; 1H); 0.05(s; 1H)	350.9 (M+H) <sup>+</sup>	4-Bromo-N- (octahydro-1,3-dioxo- 2H-isoindol-2-yl)- benzamide

Example Number	$R_6$	*NMR	**Mass Spec	Name
18		<sup>1</sup> H NMR in DMSO-d <sub>a</sub> : ō 11.05(brd, 1H); 7.83(d, 2H); 6.21(s, 2H); 3.15(s, 2H); 3.04(s, 2H); 1.66(d, 2H); 1.28(d, 2H)	373 (M-H)-	4-Bromo-N- bicyclo[2.2.2]oct-5- ene-2,3- dicarboximido- benzamide
19		<sup>1</sup> H NMR in DMSO-d <sub>e</sub> : δ 11.15(s, 1H); 7.87(d, 2H); 7.78(d, 2H); 2.04(s, 2H); 1.75-1.64(m, 2H); 1.45-1.38(m, 3H)	373 (M-H)-	4-Bromo-N- bicyclo[2.2.2]octane- 2,3-dicarboximido- benzamide

Example Number	$ m R_6$	*NMR	**Mass Spec	Name
20	H H H P P P P P P P P P P P P P P P P P	<sup>1</sup> H NMR in DMSO-d <sub>6</sub> : δ 11.36(br, 1H); 8.03(s, 4H); 5.79(s, 2H); 3.30(4H + H.O); 2.50(s, 2H); 1.20(s, 2H)	332.1 (M-H)-	4-Cyano-N- (3,3a,4,4a,5,5a,6,6a,- octallydro-1,3-dioxo- 4,6- ethenocycloprop[1]isoi ndol-2(1H)yl)- benzamide
21	H H N-N-N- CF <sub>3</sub>	<sup>1</sup> H NMR in DMSO-d <sub>6</sub> ; δ 11.286(br, 11.9); 8.13(d, 2H); 8.10(d, 2H); 3.30(4H + H <sub>2</sub> O); 1.49- 1.12 (m, 4H); 0.83(s, 1H); 0.57(s, 1H)	377.0 (M-H)-	4-Trifluoromethyl-N- (3,3a,4,4a,5,5a,6,6a,- octahydro-1,3-dioxo- 4,6- ethanocycloprop[f]isoi ndol-2(1H)-yl)- benzamide

Example Number	$ m R_6$	*NMR	**Mass Spec	Name
22	H H H D D D D D D D D D D D D D D D D D	***	***	4-Methyl-N- (3,3a,4,4a,5,5a,6,6a,- octahydro-1,3-dioxo- 4,6- ethenocycloprop[1]isoi ndol-2(1H)-yl)- benzamide
23	N. T. M. Br	***	***	3-Brome N- (1-2,2)*4,4-7,7'a- hoxelaydro 1-32' dioxospiro (pyclopropane 1,8' [4-7] methano(2H)isoindel] 2'-yl) benzamide 3-Bromo-N- (1-3,3'a-4'-7,7'a- hexalydro-1',3'- dioxospiro [cyclopropane-1,8'- [4-7] methano(2H)isoindol] 2'-yl)-benzamide

Example Number	$R_6$	*NMR	**Mass Spec	Name
24	H I Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z	***	***	N- (3,3a,4,4a,5,5a,6,6a,- octaly/dro-1,3-dioxo- 4,6- ethence/tepper[Jisoi ndo-2(H)-y-l)- tricyclo[3,3,1,13,7] decane-1-curboxamide
25	H H H H H H H H H H H H H H H H H H H	***	***	N- (3.3a,4.4a,5.5a,6.6a,- octahydro-1,3-dioxo- 4,6- eithenocycloprop[f]isoi ndol-2(1H)-yl)- benzeneacetamide

Example Number	$ m R_6$	*NMR	**Mass Spec	Name
26	H N N N N N N N N N N N N N N N N N N N	***	***	4-Bromo-N- (1,3,3a,4,7,7a- hexahydro-1,3,-dioxo- 4,7-methan-2H- isoindol-2-yl)- benzamide
27	THE CITY OF THE CI	***	***	2,4-Diehloro-N- (1,3,3a,4,7,7a- hexahydro-1,3,-dioxo- 4,7-methan-2H- isoindol-2-yl)- benzamide

Example Number	$ m R_6$	*NMR	**Mass Spec	Name
28	THE CF3	<sup>1</sup> H NMR in DMSO-d <sub>4</sub> ; δ 11.37(br. 1H); 8.10(d. 2H); 7.94 (d. 2H); 6.22(s,2H); 3.17 (s, 2H); 3.05(s, 2H); 1.66(m, 2H); 1.29 (m, 2H)	365.0 (M+H) <sup>+</sup>	4-Tritluoromethyl-N- bicyclo [2.2.2]oct-5- ene-2.3- dicarboximido- benzamide
29	DE CF3	<sup>1</sup> H NMR in DMSO-d <sub>6</sub> : δ 11.33(s, 1H); 8.14(d, 2H);8.11 (d, 2H);3.29 (s,4H); 2.05(s, 2H); 1.76-1.65(m, 4H); 1.42 (s, 2H)	367.0 (M+H) <sup>+</sup>	4-Trifluoromethyl-N- bicyclo [2.2.2]octane- 2,3-dicarboximido- benzamide

<sup>\*</sup> All 1H NMR and 13C NMR spectra were acquired on a Varian Mercury VX300 Spectrometer and referenced to tetramethysilane (TMS) unless indicated otherwise. Chemical shifts and coupling constants are reported in parts per million (ppm) and Hertz (Hz), respectively, Multiplicities indicated are: s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet, dd=doublet of doublets, and br indicates a broad signal.

\*\*Mass Spectroscopy data is expressed as a mass to charge ratio (m/z) for either (M+1) or (M-1) molecular ion.

\*\*\*indicates that data were not collected.

On page 32, please amend Table 2 as follows:

TABLE 2

Example Number	Structure	Name
30	H H H O CF3	4-Trifluoromethyl-N- (3,34,4,46,5,5a,66a-octahydro- 1,3-dioxo-4,6- ethenocycloprop[f]isoindol- 2(1H)-yl)-N-methylbenzamide

Example Number	Structure	Name
31	H H H CH <sub>3</sub>	4-Trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-N-ethylbenzamide
32	H <sub>3</sub> C H H CF <sub>3</sub>	4-Trifluoromethyl-N- (3,3a,44a,55a,6.6a-octahydro- 1,3-dioxo-7,8-dimethyl-4,6- ethenocycloprop[f]isoindol- 2(1H)-yl)-benzamide

Example Number	Structure	Name
33	OF 3	4-Trifluoromethyl-N-(3a,4,7,7a-tertahydro-4,7-etheno-1H-isoindol-2(1H)-yl)-benzamide
34	H H CH3	N-(3,3a,4,4a,5,5a,6,6a- octahydro-1,3-dioxo-7,8- dimethyl-4,6- ethenocycloprop[f]isoindol- 2(1H)-yl)-acetamide

Example Number	Structure	Name
35	H H H CH <sub>2</sub>	N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-7,8-dimethyl-4,6-ethenceycloprop[f]isoindol-2(1H)-yl)-but-3-enamide
36	H H H	N-(3,3a,4,4a,5,5a,6,6a- octahydro-1,3-ditoxo-7,8- dimethyl-4,6- ethenocycloprop[f]isoindol- 2(1Hy-yl)- cyclohexanecarboxamide

Example Number	Structure	Name
37	H H H CF3	4-Trifluoromethyl-N- (3,3a,4,4a,5,5a,6,6a-octahydro- 1,3-dioxo-7,8-dimethyl-4,6- ethenceyclporpof[pisoindol- 2(1H)-yl)-benzylacetamide
38	H H N N N N N N N N N N N N N N N N N N	4-Pyridyl-N- (3,3a,4,4a,5,5a,6,6a-octahydro- 1,3-diox-7,8-dimethyl-4,6- ethenocycloprop[f]isoindol- 2(1H)-yl)-acetamide

Example Number	Structure	Name
39	H H H N N N N N N N N N N N N N N N N N	3 Thienyl N. (3-3a,4/as,5-8a,6-a octahydro-1,3-dioxo-7,8-dimethyl 4,6-ethenocycloprop(filsoindol-2(HF)-yl) N-methylbenzamide 3-Thienyl-N: (3-3a,4/as,5-a,6-6a-octahydro-1,3-dioxo-7,8-dimethyl-4,6-ethenocycloprop(filsoindol-2(HF)-yl)acetamide
40	H N H CF <sub>3</sub>	4-(Trifluoromethyl)-N- [(3aR.45,4aS,5aR.6K,6aS)- 3,3a,4.4a,5,6,6a-cctahydro- 1,3-dioxo-4,6- ethenocycloprop[f]isoindol- 2(1H)-yl]-benzamide
41	H <sub>3</sub> C	2,4-Dimethyl-N- (3,3a,4,4a,5,5a,6,6a-octahydro- 1,3-dioxo-4,6- ethencycloprop[]isoindol- 2(1Hyyl)-hiazole-5- carboxamide